Clarity Pharmaceuticals (ASX:CU6) Days Payable: 0.00 (As of Dec. 2025)


ASX:CU6 Clarity Pharmaceuticals Ltd ASX:CU6
39 GF Score
Price A$1.82
! 2 Warning Signs
View Full Analysis

What is Clarity Pharmaceuticals Days Payable?

Clarity Pharmaceuticals ASX:CU6 -11.03% 39 Days Payable is 0.00 as of Dec. 2025. GuruFocus rates ASX:CU6 with a GF Score™ of 39/100. The stock has 2 warning signs investors should review. Among 706 Biotechnology companies, Clarity Pharmaceuticals ranks worse than 141642.92% on this metric.

Clarity Pharmaceuticals's average Accounts Payable for the six months ended in Dec. 2025 was A$11.71 Mil. Clarity Pharmaceuticals's Cost of Goods Sold for the six months ended in Dec. 2025 was A$0.00 Mil.

The historical rank and industry rank for Clarity Pharmaceuticals's Days Payable or its related term are showing as below:

ASX:CU6's Days Payable is not ranked *
in the Biotechnology industry.
Industry Median: 113.56
* Ranked among companies with meaningful Days Payable only.

Clarity Pharmaceuticals's Days Payable stayed the same from Dec. 2024 (0.00) to Dec. 2025 (0.00).

Clarity Pharmaceuticals Days Payable Historical Data

* Premium members only.

The historical data trend for Clarity Pharmaceuticals's Days Payable can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Clarity Pharmaceuticals Days Payable Chart

Clarity Pharmaceuticals Annual Data
Trend Jun22 Jun23 Jun24 Jun25
Days Payable
0.00 0.00 0.00 0.00

Clarity Pharmaceuticals Semi-Annual Data
Dec20 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24 Dec24 Jun25 Dec25
Days Payable Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00

ASX:CU6 vs VRTX, REGN, ALNY: Days Payable Comparison

For the Biotechnology subindustry, Clarity Pharmaceuticals's Days Payable, along with its competitors' market caps and Days Payable data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Clarity Pharmaceuticals Days Payable vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Clarity Pharmaceuticals's Days Payable distribution charts can be found below:

* The bar in red indicates where Clarity Pharmaceuticals's Days Payable falls into.


ASX:CU6
39GF Score
Clarity Pharmaceuticals Ltd ASX:CU6
Days Payable is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Clarity Pharmaceuticals Days Payable Calculation

Days Payable indicates the number of days that the account payable relative to cost of goods sold the company has. An increase of Days Payable may suggest that the company delays paying its suppliers.

Clarity Pharmaceuticals's Days Payable for the fiscal year that ended in Jun. 2025 is calculated as

Days Payable (A: Jun. 2025 )
=Average Accounts Payable /Cost of Goods Sold*Days in Period
=( (Accounts Payable (A: Jun. 2024 ) + Accounts Payable (A: Jun. 2025 )) / count ) / Cost of Goods Sold (A: Jun. 2025 )*Days in Period
=( (2.084 + 3.206) / 2 ) / 0*365
=2.645 / 0*365
=N/A

Clarity Pharmaceuticals's Days Payable for the quarter that ended in Dec. 2025 is calculated as:

Days Payable (Q: Dec. 2025 )
=Average Accounts Payable / Cost of Goods Sold*Days in Period
=( (Accounts Payable (Q: Jun. 2025 ) + Accounts Payable (Q: Dec. 2025 )) / count ) / Cost of Goods Sold (Q: Dec. 2025 )*Days in Period
=( (3.206 + 20.213) / 2 ) / 0*365 / 2
=11.7095 / 0*365 / 2
=N/A

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Days Payable →
What does a Days Payable of 0.00 mean?
Clarity Pharmaceuticals (ASX:CU6) has a Days Payable of 0.00 as of Dec. 2025. Days payable represents the average amount of days a company waits to pay its invoices from suppliers. View historical data on Clarity Pharmaceuticals and its competitors. According to the industry distribution chart, Clarity Pharmaceuticals ranks #999999 out of 706 companies in the Biotechnology industry.
Is Clarity Pharmaceuticals' Days Payable too high?
Clarity Pharmaceuticals' current Days Payable is 0.00. Based on the distribution chart, Clarity Pharmaceuticals ranks #999999 out of 706 companies in the Biotechnology industry, which is in the bottom quartile relative to peers. Overall, Clarity Pharmaceuticals has a GF Score™ of 39/100, reflecting its overall financial health beyond just this single metric.
How does Clarity Pharmaceuticals' Days Payable compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Clarity Pharmaceuticals ranks #999999 out of 706 companies for Days Payable. This places Clarity Pharmaceuticals in the lower half of its industry. The industry median Days Payable is 113.56. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Days Payable for a Biotechnology company?
The median Days Payable among Biotechnology companies is 113.56, based on 706 companies in the industry. Companies in the top quartile (top 25%) have a Days Payable significantly above this median, while those in the bottom quartile fall well below. However, Days Payable should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Days Payable mean?
A high Days Payable can signal that a stock is expensive relative to its fundamentals. Days payable represents the average amount of days a company waits to pay its invoices from suppliers. View historical data on Clarity Pharmaceuticals and its competitors. For the Biotechnology industry, the median Days Payable is 113.56 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Clarity Pharmaceuticals's current Days Payable is 0.00. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Clarity Pharmaceuticals stock overvalued right now?
Clarity Pharmaceuticals (ASX:CU6) has a current Days Payable of 0.00. The current Days Payable is 0.00. Clarity Pharmaceuticals' overall GF Score™ is 39/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Days Payable calculated?
Days Payable is calculated from a company's financial statements. For Clarity Pharmaceuticals (ASX:CU6), the current Days Payable is 0.00 as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Clarity Pharmaceuticals Business Description

Other Exchanges CLRPF:USA1F4:Germany
Address 2-4 Cornwallis Street, Suite 212a, National Innovation Centre, Eveleigh, Sydney, NSW, AUS, 2015
Clarity Pharmaceuticals Ltd is a clinical-stage radiopharmaceutical company developing next-generation theranostic (therapy and imaging) products, using its SAR Technology platform. Clarity's Targeted Copper Theranostic (TCT) platform of products utilize pairing of copper isotopes, specifically copper-64 (Cu-64 or 64Cu) for imaging and copper-67 Cu-67 or 67Cu) for therapy, which delivers accuracy and precision in the treatment of a range of cancers. The company's clinical development pipeline includes SAR-bisPSMA, SAR-Bombesin, and Sartate, in their different stages of development for the diagnosis and/or treatment of various cancers. Clarity operates in a single segment, which is the development of radiopharmaceuticals. Geographically, it operates in Australia and the United States.
39GF Score

Get the complete analysis for ASX:CU6

Days Payable is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

A$1.82
Price